抗病毒治疗在HBV相关肝癌综合治疗中的作用*

doi:10.3969/j.issn.1672-5069.2015.02.002

实用肝脏病杂志 ›› 2015, Vol. 18 ›› Issue (2): 115-117.doi: 10.3969/j.issn.1672-5069.2015.02.002

抗病毒治疗在HBV相关肝癌综合治疗中的作用^*

周伟平, 尹磊, 吴孟超

200438 上海市第二军医大学东方肝胆外科医院

收稿日期:2014-12-30 出版日期:2015-03-10 发布日期:2016-02-19
作者简介:周伟平,男,55岁,教授,主任医师,博士生导师。主要研究方向：肝脏肿瘤的外科治疗及病毒相关性肝癌的综合治疗。E-mail：EHPHWP@126.com
基金资助:
国家传染病“十二五”重大专项（2012ZX10002010）; 国家重大科技攻关973项目（2014CB542102）; 国家自然科学基金创新团队项目（81221061）

Antiviral therapy in patients with hepatitis B viral infection-related primary liver cancer

Zhou Weiping, Yin Lei, Wu Mengchao

Eastern Hepatobiliary Hospital,Affiliated to Second Military Medical University,Shanghai 200438

Received:2014-12-30 Online:2015-03-10 Published:2016-02-19

摘要/Abstract

关键词: 肝癌, 乙型肝炎, 抗病毒治疗

Key words: Hepatoma, Hepatitis B, Antiviral therapy

周伟平, 尹磊, 吴孟超. 抗病毒治疗在HBV相关肝癌综合治疗中的作用^*[J]. 实用肝脏病杂志, 2015, 18(2): 115-117.

Zhou Weiping, Yin Lei, Wu Mengchao. Antiviral therapy in patients with hepatitis B viral infection-related primary liver cancer[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(2): 115-117.

[1] Chen CJ,Yang HI,Su J,et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA,2006,295（1）:65-73.
[2] Wu JC,Huang YH,Chau GY,et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol,2009,51（5）:890-897.
[3] Lai CL,Yuen MF. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology,2013,57（1）:399-408.
[4] Huang G,Lau WY,Shen F,et al. Preoperative hepatitis B virus DNA level is a risk factor for postoperative liver failure in patients who underwent partial hepatectomy for hepatitis B-related hepatocellular carcinoma. World J Surg,2014,38（9）:2370-2376.
[5] Huang G,Yang Y,Shen F,et al. Early viral suppression predicts good postoperative survivals in patients with hepatocellular carcinoma with a high baseline HBV DNA load. Ann Surg Oncol,2013,20（5）:1482-1490.
[6] Lee JI,Kim JK,Chang HY,et al. Impact of postoperative hepatitis B virus reactivation in hepatocellular carcinoma patients who formerly had naturally suppressed virus. J Gastroenterol Hepatol,2014,29（5）:1019-1027.
[7] Yeo W,Zee B,Zhong S,et al. Comprehensive analysis of risk factors associating with epatitis B virus （HBV） reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer. 2004,90（7）:1306-1311.
[8] Huang W,Zhang W,Fan M,et al. Risk factors for hepatitis B virus reactivation after conformal radiotherapy in patients with hepatocellular carcinoma.Cancer Sci,2014,105（6）:697-703.
[9] Jang JW,Choi JY,Bae SH,et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology,2006,43（2）:233-240.
[10] Kim JH,Park JW,Kim TH,et al. Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in patients with hepatitis B virus-related hepatocellular carcinoma. Int J Radiat Oncol Biol Phys,2007,69（3）:813-819.
[11] Yeo W,Lam KC,Zee B,et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol,2004,15（11）:1661-1666.
[12] Urata Y,Kubo S,Takemura S,et al. Effects of antiviral therapy on long-term outcome after liver resection for hepatitis B virus-related hepatocellular carcinoma.J Hepatobiliary Pancreat Sci,2012,19（6）:685-696.
[13] Liaw YF,Sung JJ,Chow WC,et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med,2004,351（15）:1521-1531.
[14] Lai CL,Chien RN,Leung NW,et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med,1998,339（2）:61-68.
[15] Lai CL,Gane E,Liaw YF,et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med,2007,357（25）:2576-2588.
[16] Chang TT,Liaw YF,Wu SS,et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology,2010,52（3）:886-893.
[17] Wong JS, Wong GL,Tsoi KK,et al. Meta-analysis:the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther,2011,33（10）:1104-1112.
[18] Wu CY,Chen YJ,Ho HJ,et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA,2012,308（18）:1906-1914.
[19] Koda M,Nagahara T,Matono T,et al. Nucleotide analogs for patients with HBV-related hepatocellular carcinoma increase the survival rate through improved liver function. Intern Med,2009,48（1）:11-17.
[20] Yin J,Li N,Han Y,et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma:a two-stage longitudinal clinical study. J Clin Oncol, 2013, 31（29）:3647-3655.
[21] Lao XM,Luo G,Ye LT,et al. Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma. Liver Int,2013,33（4）:595-604.
[22] Dan JQ,Zhang YJ,Huang JT,et al. Hepatitis B virus reactivation after radiofrequency ablation or hepatic resection for HBV-related small hepatocellular carcinoma:a retrospective study. Eur J Surg Oncol,2013,39（8）:865-872.
[23] Kim YS,Lim HK,Rhim H,et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol,2013,58（1）:89-97.
[24] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志,2011,14（2）：81-89.
[25] 中华人民共和国卫生部.原发性肝癌诊疗规范（2011年版）. 临床肝胆病杂志,2011,27（11）:1141-1159.

抗病毒治疗在HBV相关肝癌综合治疗中的作用^*

Antiviral therapy in patients with hepatitis B viral infection-related primary liver cancer

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[2]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[3]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[4]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[5]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[6]	马丽英, 沈利娟. 妊娠后期应用替诺福韦治疗血清HBV高载量孕妇阻断HBV母婴传播的疗效及安全性分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 836-839.
[7]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[8]	邢昊, 韩骏, 杨田. 应用血清PIVKA-II诊断肝细胞癌研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 934-937.
[9]	杜科业, 杨东亮, 刘嘉. 慢性乙型肝炎与调节性T细胞研究进展^*[J]. 实用肝脏病杂志, 2019, 22(5): 613-616.
[10]	廖桂婵, 彭颉, 张小勇. 肝细胞介导的天然免疫应答参与控制乙型肝炎病毒感染^*[J]. 实用肝脏病杂志, 2019, 22(5): 617-619.
[11]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[12]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.
[13]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[14]	朱玉成, 闫家微, 孙景坤, 张秋月. 慢加急性肝衰竭患者血清二胺氧化酶水平及其临床意义探讨*[J]. 实用肝脏病杂志, 2019, 22(5): 672-675.
[15]	张梅, 石秀英, 李林娟, 薛亚妮. 肝源性糖尿病患者肝组织干扰素诱导蛋白-10表达变化*[J]. 实用肝脏病杂志, 2019, 22(5): 688-691.